Shilpa Medicare Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Shilpa Medicare and mAbTree Biologics receive FDA Orphan Drug Designation, Advancing Treatment for Rare Blood Cancers".
Press Release Jan 28 2026
Earlier from Shilpa Medicare
- Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
- Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
- Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
- Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics